Recombinant hepatitis B vaccine (Engerix-B®): A review of its immunogenicity and protective efficacy against hepatitis B

Drugs

Volumn 63, Issue 10, 2003, Pages 1021-1051

  Keating, Gillian M ^a   Noble, Stuart ^a   Averhoff, F M ^b   Belloni, C ^c   Duval, B ^d   Goldwater, P N ^e   Hall, A J ^f   Honorati, M C ^g   Kallinowski, B ^h   Leroux Roels, G ⁱ   Poovorawan, Y ^j  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ GHENT UNIVERSITY   (Belgium)

^j CHULALONGKORN UNIVERSITY   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS VACCINE; HEPAVAX GENE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID;

ACTIVE IMMUNIZATION; ALCOHOLISM; ARTHRALGIA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SURVEILLANCE PROGRAM; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE PERSONNEL; HEMODIALYSIS; HEPATITIS B; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE; MALAISE; MYALGIA; NAUSEA; NONHUMAN; PARESTHESIA; PRURITUS; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; URTICARIA; VACCINATION; VERTIGO; VIRUS CARRIER; VOMITING;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; VACCINATION; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0037716983     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363100-00006     Document Type: Review

References (250)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 Dec 11; 337 (24): 1733-45
2. Lee PI, Lee CY. Practical considerations in converting from plasma-derived to recombinant hepatitis B vaccines. Biodrugs 1998; 10 (1): 11-25
3. Heermann KH, Goldmann U, Schwartz W, et al. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984 Nov; 52 (2): 396-402
4. François G, Kew M, Van Damme P, et al. Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine 2001; 19: 3799-815
5. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997 Aug; 43 (8B): 1500-6
6. Zimmerman RK, Ruben FL, Ahwesh ER. Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin. J Fam Pract 1997 Oct; 45 (4): 295-315
7. Garrison MW, Baker DE. Therapeutic advances in the prevention of hepatitis B: yeast-derived recombinant hepatitis B vaccines. DICP 1991 Jun; 25 (6): 617-27
8. Vryheid RE, Kane MA, Muller N, et al. Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 2001; 19: 1026-37
9. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001; 10: 751-74
10. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993 May; 12 (5): 438-45
11. Stephenne J. Production in yeast versus mammalian cells of the first recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine. Adv Biotechnol Processes 1990; 14: 279-99
12. Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 2000; 18: 57-67
13. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: A review of its immunogenicity and protective efficacy against hepatitis B. Biodrugs 1998; 10 (2): 137-58
14. Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian J Trop Med Public Health 1991 Mar; 22 (1): 39-40
15. Ferreri R, Adinolfi B, Limardi C, et al. Hepatitis B vaccination: evaluation of a short-interval dosing schedule in low-weight newborns. Curr Ther Res 1992 Sep; 52 (3): 493-7
16. Golebiowska M, Kardas-Sobantka D, Chlebna-Sokól D, et al. Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999 Apr; 158: 293-7
17. Gunn TR, Bosley A, Woodfield DG. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N Z Med J 1989 Jan 25; 102 (860): 1-3
18. Gunn TR, Woodfield DG. The persistence of anti-hepatitis B surface antibodies to three years of age: is a hepatitis B vaccine booster required? N Z Med J 1993 Nov 24; 106: 499-501
19. Meheus A, Alisjahbana A, Vranckx R, et al. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates. Postgrad Med J 1987; 63 Suppl. 2: 139-41
20. Cadranel S, Zeghlache S, Fernandez S, et al. Vaccination of newborns of HBsAg-positive carrier mothers with a recombinant DNA hepatitis B vaccine. Postgrad Med J 1987; 63 Suppl. 2: 159-60
21. Kuru U, Turan O, Kuru N, et al. Results of vaccinated infants born to HBsAg-positive mothers with different hepatitis B vaccines and doses. Turk J Pediatr 1995; 37: 93-102
22. Mittal SK, Rao S, Kumari S, et al. Simultaneous administration of hepatitis B vaccine with other E.P.I. vaccines. Indian J Pediatr 1994; 61 (2): 183-8
23. Palmović D, Crnjaković-Palmović J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 1994 Oct; 10: 541-7
24. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989 Jun 9; 261 (22): 3278-81
25. Moyes C, Milne A. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children. N Z Med J 1988 Apr 13; 101 (843): 162-4
26. Wilkinson SE, Morath M, Bennett DL, et al. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health 1996 Feb; 32: 60-2
27. Rumi MG, Romeo R, Bortolini M, et al. Immunogenicity of a yeast-recombinant hepatitis B vaccine in high-risk children. J Med Virol 1989 Jan; 27 (1): 48-51
28. Crovari P, Crovari PC, Petrilli RC, et al. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults. Postgrad Med J 1987; 63 Suppl. 2: 161-4
29. Dajani AI, Wasef SF, Fikri M. Hepatitis B vaccination: A clinical trial of the yeast derived recombinant DNA hepatitis B vaccine. Emirates Med J 1987; 5 (3): 189-93
30. Degrassi A, Mariani E, Honorati MC, et al. Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine. Vaccine 1992; 10 (9): 617-22
31. Hammond GW, Parker J, Mimms L, et al. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines. Vaccine 1991 Feb; 9 (2): 97-100
32. Isahak I, Abdul Malik Y, Hakim AS, et al. The evaluation of Engerix-B in healthy Malaysian medical students. Singapore Med J 1990 Aug; 31 (4): 314-6
33. Leroux-Roels G, Van Hecke E, Michielsen W, et al. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994 Jul; 12 (9): 812-8
34. Möst J, Larcher C, Vogetseder W, et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students. Vaccine 1992; 10 (11): 740-1
35. Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenecity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998 Apr; 16 (7): 708-14
36. Wiström J, Ahlm C, Lundberg S, et al. Booster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999 Apr 23; 17 (17): 2162-5
37. Aspinall S, Hauman CHJ, Bos P, et al. Varying antibody response in dental health care workers vaccinated with recombinant hepatitis B vaccine. J Dent Assoc S Afr 1991 Jun; 46 (6): 321-4
38. Zanetti AR, Tanzi E, Romano L, et al. Yeast-derived hepatitis B vaccine in dental students: a three-year follow-up study. Vaccine 1990; 8 (3): 205-8
39. Chang PC, Schrander-van der Meer AM, van Dorp WT, et al. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996 Jan; 11: 191-3
40. Docci D, Cipolloni PA, Baldrati L, et al. Immune response to a recombinant hepatitis B vaccine in hemodialysis patients. Int J Artif Organs 1990 Jul; 13 (7): 451-3
41. Docci D, Cipolloni PA, Mengozzi S, et al. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: a two-year follow-up. Nephron 1992; 61 (3): 352-3
42. Fanelli V, Sanna G, Solinas A. Expectation of impaired response to recombinant hepatitis B vaccination. Nephron 1992; 61 (3): 293-5
43. Faranna P, Cozzi G, Belloni M, et al. Immunization and vaccination protocol in hemodialysis patients with naturally acquired hepatitis B antibody. Nephron 1992 Jul; 61: 311-2
44. Guan R, Tay HH, Choong HL, et al. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: the immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Ann Acad Med Singapore 1990 Nov; 19 (6): 793-7
45. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol 2002; 58 (4): 301-4
46. Jaiswal SB, Salgia PB, Sepaha AG, et al. Hepatitis B vaccine in patients on haemodialysis. Lancet 1995 Jul 29; 346: 317-8
47. Mettang T, Schenk U, Thomas S, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure: a preliminary study. Nephron 1996 Feb; 72: 192-6
48. Navarro JF, Teruel JL, Mateos M. et al. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients. Clin Nephrol 1994 Feb; 41 (2): 113-6
49. Poux JM, Ranger S, Lagarde C, et al. Efficacy of intradermal injection of recombinant hepatitis B vaccine in dialysis patients [letter]. Nephrol Dial Transplant 1994; 9 (8): 1213-4
50. Vlassopoulos DA, Arvanitis DK, Lilis DS, et al. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int J Artif Organs 1999 Nov; 22: 739-43
51. Vlassopoulos D, Arvanitis D, Lilis D, et al. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997; 19 (3): 455-60
52. Berner J, Kadian M, Post J, et al. Prophylactic recombinant hepatitis B vaccine in patients undergoing orthotopic liver transplantation. Transplant Proc 1993 Apr; 25 (2): 1751-2
53. Duca P, Del Pont JM, D'Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr 2001 Feb; 32 (2): 168-70
54. Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001 Apr; 13 (4): 363-7
55. Hess G, Rossol S, Voth R, et al. Active immunization of homosexual men using a recombinant hepatitis B vaccine. J Med Virol 1989 Dec; 29 (4): 229-31
56. Li Volti S, Di Gregorio F, Romeo MA, et al. Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 157-60
57. Mannucci PM, Gringeri A, Morfini M, et al. Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs. Am J Hematol 1988 Dec; 29 (4): 211-4
58. Vajro P, Lettera P, Fontanella A, et al. Vaccination against hepatitis B in preschool children with Down's syndrome. J Intellect Disabil Res 1992 Feb; 36: 77-81
59. Wismans PJ, van Hattum J, de Gast GC, et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991 Nov; 35 (3): 216-22
60. Centers for Disease Control and Prevention. Recommendations of the Immunization Practices Advisory Committee (ACIP): recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 1985 Jun 7; 34 (22): 313-24, 329-35
61. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000 Feb 12; 355: 561-5
62. Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? J Infect Dis 1999 Feb; 179: 489-92
63. GlaxoSmithKline. Engerix-B® prescribing information [on-line]. Available from URL: http://www.gsk.com [Accessed 2002 Dec 10]
64. Alikasifoglu M, Çullu F, Kutlu T, et al. Comparison study of the immunogenicity of different types and dosages of recombinant hepatitis B vaccine in healthy neonates [letter]. J Trop Pediatr 2001 Feb; 47 (1): 60-2
65. Amani A, Shokri F. Immunogenicity of recombinant hepatitis B vaccine in Iranian neonates: high frequency of unresponsiveness independent of the cartier state of mothers. Iran J Med Sci 1995; 20 (3-4): 87-92
66. Belson A, Reif S, Peled Y, et al. Immune response to hepatitis B virus vaccine in 1-year-old preterm and term infants. J Pediatr Gastroenterol Nutr 1996 Oct; 23 (3): 252-5
67. Blondheim O, Bader D, Abend M, et al. Immunogenicity of hepatitis B vaccine in preterm infants. Arch Dis Child 1998 Nov; 79 (Fetal ed.): 206-8
68. Chirico G, Belloni C, Gasparoni A, et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 1993; 92: 717-9
69. Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, et al. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine 2002 Feb 22; 20: 1557-62
70. Goldfarb J, Baley J, Medendorp SV, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B® hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994 Jan; 13 (1): 18-22
71. Yerushalmi B, Raz R, Blondheim O, et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997 Jun; 16 (6): 587-92
72. Cook IF, Murtagh J. Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants. J Paediatr Child Health 2002; 38 (4): 393-6
73. Belloni C, Pistorio A, Tinelli C, et al. Early immunisation with hepatitis B vaccine: a five-year study. Vaccine 2000 Jan 31; 18: 1307-11
74. Jaber L, Merlob P, Samra Z. Response to recombinant yeast-derived hepatitis B vaccine in Arab infants. Int J Risk Saf Med 1999; 12 (3-4): 193-6
75. Linder N, Vishne TH, Levin E, et al. Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols. Infection 2002 Jun; 30: 136-9
76. El-Sawy IH, Mohamed ON. Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children. East Mediterr Health J 1999 Sep; 5 (5): 922-32
77. Goldfarb J, Medendorp SV, Garcia H, et al. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of a recombinant hepatitis B vaccine in healthy infants. Pediatr Infect Dis J 1996 Sep; 15 (9): 764-7
78. Greenberg DP, Vadheim CM, Wong VK, et al. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr Infect Dis J 1996 Jul; 15 (7): 590-6
79. Lee CY, Lee PI, Huang LM, et al. A simplified schedule to integrate the hepatitis B vaccine into an expanded program of immunization in endemic countries. J Pediatr 1997 Jun; 130 (6): 981-6
80. Giammanco G, Li Volti S, Mauro L, et al. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine 1991 Oct; 9 (10): 747-50
81. Salmaso S, Piscitelli A, Rapicetta M, et al. Immunogenicity of hepatitis B vaccines among infant recipients of acellular and whole cell pertussis DTP vaccines. Vaccine 1998 Apr; 16 (6): 643-6
82. Aristegui J, Muñiz J, Pérez Legorburu A, et al. Newborn universal immunisation against hepatitis B: immunogenicity and reactogenicity of simultaneous administration of diphtheria/tetanus/pertussis (DTP) and oral polio vaccines with hepatitis B vaccine at 0, 2 and 6 months of age. Vaccine 1995 Aug; 13 (11): 973-7
83. Da Villa G, Picciotto L, Ribera G, et al. Effective antibody response in newborn babies living in Maldives to simultaneous vaccination against hepatitis B, poliomyelitis, diphtheria and tetanus. Vaccine 1995 Jun; 13 (9): 795-8
84. Catania G, Di Ciommo V, Concato C. Vaccination against hepatitis B virus in children and adolescents in a pediatric hospital. Recenti Prog Med 1996 Jun; 87 (6): 271-4
85. Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 1995 Oct 18; 274 (15): 1209-13
86. Dural B, Boulianne N, De Serres G, et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 2000 Feb 14; 18 (15): 1467-72
87. Halsey NA, Moulton LH, O'Donovan JC, et al. Hepatitis B vaccine administered to children and adolescents at yearly intervals. Pediatrics 1999 Jun; 103 (6): 1243-7
88. Leroux-Roels G, Abraham B, Fourneau M, et al. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 2000 Nov 22; 19 (7-8): 937-42
89. Plaitano S, Sagliocca L, Mele A, et al. Hepatitis B mass immunization of adolescents: a pilot study in a community. Eur J Epidemiol 1993 May; 9 (3): 307-10
90. Poovorawan Y, Pongpunlert W, Theamboonlers A, et al. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20μg and 10μg doses of hepatitis B vaccine in adolescents. Southeast Asian J Trop Med Public Health 1993 Jun; 24 (2): 255-9
91. Raz R, Dagan R, Gallil A, et al. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 1996 Feb; 14 (3): 207-11
92. Simó Minana J, Gaztambide Ganuza M, Fernández Millan P, et al. Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination. Vaccine 1996 Feb; 14 (2): 103-6
93. Middleman AB, Kozinetz CA, Robertson LM, et al. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis B immunization among adolescents. Pediatrics 2001 May; 107 (5): 1065-9
94. Ferreira CRB, Yoshida CFT, Mercadante LAC, et al. Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 mcg). Rev Inst Med Trop São Paulo 1993; 35 (1): 89-92
95. Goldfarb J, Medendorp SV, Nagamori K, et al. Comparison study of the immunogenicity and safety of 5- and 10-μg dosages of a recombinant hepatitis B vaccine in healthy children. Pediatr Infect Dis J 1996 Sep; 15 (9): 768-71
96. Schiff GM, Sherwood JR, Zeldis JB, et al. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995 Jan; 16 (1): 12-7
97. Manyike PT, Aspinall S, Summers RS. Immunogenicity of recombinant hepatitis B vaccine in urban black children from Ga-Rankuwa, Bophuthatswana, South Africa. Pediatr Infect Dis J 1992 Sep; 11 (9): 726-30
98. Dobson S, Scheifele D, Goilav C. Alternative vaccination schedule for a recombinant hepatitis B vaccine (Engerix-B) [abstract]. 5th International Forum on Global Vaccinology; 2001 Oct 15-17; Minsk
99. Chen CC, Chang MH, Lee HC, et al. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule. Acta Paediatr Sin 1999; 40 (3): 157-60
100. Heron LG, Chant KG, Jalaludin BB. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 2002 Oct 4; 20 (29-30): 3472-6
101. Bock HL, Kruppenbacher J, Sänger R, et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996 Oct 28; 156 (19): 2226-31
102. Chiaramonte M, Majori S, Ngatchu T, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996 Feb; 14 (2): 135-7
103. Hohler T, Stradnann-Bellinghausen B, Starke R, et al. C4A deficiency and nonresponse to hepatitis B vaccination. J Hepatol 2002; 37: 387-92
104. Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine 2001 Sep 14; 19 (32): 4710-9
105. Levie K, Gjorup I, Skinhøj P, et al. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002; 34 (8): 610-4
106. Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J 2001 May; 3 (5): 328-32
107. Scheiermann N, Gesemann M, Maurer C, et al. Persistence of antibodies after immunization with a recombinant, yeast- derived hepatitis B vaccine following two different schedules. Vaccine 1990 Mar; 8 Suppl.: S44-6
108. Van Damme P, Cramm M, Safary A, et al. Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine 1992; 10 (6): 366-7
109. de Rave S, Heijtink RA, Bakker-Bendik M, et al. Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers. Vaccine 1994 May; 12 (6): 532-4
110. Treadwell TL, Keeffe EB, Lake J, et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993 Dec; 95 (6): 584-8
111. Harries AD, Clark M, Beeching NJ, et al. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991 Nov; 23: 251-4
112. Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001 Feb 28; 19 (15-16): 2055-60
113. Bock HL, Löscher T, Scheiermann N, et al. Accelerated schedule for hepatitis B immunization. J Travel Med 1995; 2 (4): 213-7
114. Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 1997 Nov; 15 (16): 1724-31
115. Rustgi VK, Schleupner CJ, Krause DS. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine 1995 Dec; 13 (17): 1665-8
116. Van Herck K, Van Damme P, Thoelen S, et al. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. Vaccine 1998 Dec; 16 (20): 1933-5
117. Dentico P, Buongiorno R, Volpe A, et al. The influence of high intrafamilial spread of HBV on the persistence of response to hepatitis B vaccine in newborns of HBsAg positive mothers. J Prey Med Hyg 1995; 36 (1-2): 75-8
118. Grosheide PM, del Canho R, Voogd M, et al. Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Vaccine 1994 Sep; 12 (12): 1059-63
119. Hieu NT, Kim KH, Janowicz Z, et al. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 2002 Mar 15; 20 (13): 1803-8
120. Lee PI, Lee CY, Huang LM, et al. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995 May; 126 (5 Pt 1): 716-21
121. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, et al. Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child 1997 Jul; 77 (Fetal Ed): 47-51
122. Huang LM, Chiang BL, Lee CY, et al. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999 Mar; 29: 954-9
123. GlaxoSmithKline. Engerix B: summary of product characteristics [online]. Available from URL: http://www.gsk.com [Accessed 2002 Dec 9]
124. Panda SK, Ramesh R, Rao KVS, et al. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants. J Med Virol 1991 Dec; 35 (4): 297-302
125. Marsano LS, Greenberg RN, Kirkpatrick RB, et al. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am J Gastroenterol 1996 Jan; 91 (1): 111-5
126. Just M, Berger R, Just V. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults. Postgrad Med J 1987; 63 Suppl. 2: 121-3
127. Marinho RT, Moura MC, Pedro M, et al. Hepatitis B vaccination in hospital personnel and medical students. J Clin Gastroenterol 1999 Jun; 28 (4): 317-22
128. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15 (1): 1-8
129. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 2000 Jan 6; 18: 1074-80
130. Honorati MC, Mariani E, Dolzani P, et al. Biological parameters influencing the immunological response to plasma derived and recombinant hepatitis B vaccines. Ann Ist Super Sanit́ 1996; 32 (3): 369-74
131. Payton CD, Scarisbrick DA, Sikotra S, et al. Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidemiol Infect 1993 Feb; 110 (1): 177-80
132. Rogan PD, Duguid JKM. Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine. J Infect 1991 Jan; 22 (1): 5-9
133. Struve J, Aronsson B, Frenning B, et al. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis 1992; 24 (4): 423-9
134. Turohi MD, Martelli CMT, Ferraz ML, et al. Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine. Rev Inst Med Trop São Paulo 1997; 39 (1): 15-9
135. Henderson EA, Louie TJ, Ramotar K, et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000 Apr; 21: 264-9
136. Bush LM, Moonsammy GI, Boscia JA. Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. Vaccine 1991; 9 (11): 807-9
137. Ramon JM, Bou R, Oromi J. Low-dose intramuscular revaccination against hepatitis B. Vaccine 1996 Dec; 14 (17-18): 1647-50
138. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 1999 Feb; 47: 183-5
139. El-Reshaid K, Al-Mufti S, Johny KV, et al. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 1994; 12 (3): 223-8
140. Peces R, de la Torre M, Alcázar R, et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997 Feb; 29 (2): 239-45
141. Sezer S, Özdemir FN, Güz G, et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000 May; 32: 607-8
142. Bruguera M, Rodicio JL, Alcazar JM, et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990 Mar; 8 Suppl.: S47-9
143. Rault R, Freed B, Nespor S, et al. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. ASAIO J 1995; 41 (3): M717-9
144. Dentico P, Volpe A, Buongiorno R, et al. Immunogenicity and efficacy of anti-hepatitis B vaccines in hemodialysis patients. Nephron 1992 Jul; 61: 324-5
145. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72 (4): 536-43
146. Krishnamurthy G, Kher V, Naik S. Immunogenicity and efficacy of hepatitis B vaccination in Indian chronic renal failure patients on hemodialysis and after renal transplantation. Nephron 1996 Oct; 74: 424-5
147. Paynter HE, Clarke J, McArley A, et al. Hepatitis B vaccination. Nephrol Dial Transplant 1997 Mar; 12 (3): 623-4
148. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991 Jul; 40 (1): 121-8
149. Quiroga JA, Castillo I, Porres JC, et al. Recombinant γ-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990 Oct; 12 (4 Pt 1): 661-3
150. Kapoor D, Aggarwal SR, Singh NP, et al. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999 Sep; 6 (5): 405-9
151. Polychronopoulou-Androulakaki S, Panagiotou JP, Kostaridou S, et al. Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine. Pediatr Hematol Oncol 1996; 13 (5): 425-31
152. Goyal S, Pai SK, Kelkar R, et al. Hepatitis B vaccination in acute lymphoblastic leukemia. Leuk Res 1998 Feb; 22 (2): 193-5
153. Somjee S, Pai S, Kelkar R, et al. Hepatitis B vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule. Leuk Res 1999 Apr; 23: 365-7
154. Yetgin S, Tunç B, Koç A, et al. Two booster dose hepatitis B virus vaccination in patients with leukemia. Leuk Res 2001 Aug; 25: 647-9
155. Rokicka-Milewska R, Jackowska T, Sopylo B, et al. Active immunization of children with leukemias and lymphomas against infection by hepatitis B virus. Acta Paediatr Jpn 1993; 35 (5): 400-3
156. Styczyński J, Wysocki M, Koltan S, et al. Long-term effects of vaccination against hepatitis virus B infection in children with neoplastic disease. Med Sci Monit 1997; 3 (6): 864-8
157. Awofeso N, Levy M, Harper S, et al. Response to HBV vaccine in relation to vaccine dose and anti-HCV positivity: a New South Wales correctional facilities' study. Vaccine 2001; 19: 4245-548
158. Van Damme P, Vranckx R, Safary A, et al. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med 1989 Sep 4; 87 Suppl. 3A: 26S-9S
159. Vellinga A, Van Damme P, Weyler JJ, et al. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine 1999; 17: 602-6
160. Goilav C, Prinsen H, Piot P. Protective efficacy of a recombinant DNA vaccine against hepatitis B in male homosexuals: results at 36 months. Vaccine 1990 Mar; 8 Suppl.: S50-2
161. Laukamm-Josten U, von Laer G, Feldmeier H, et al. Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J 1987; 63 Suppl. 2: 143-6
162. Santagostino E. Mannucci PM, Gringeri A, et al. Accelerated schedule of hepatitis B vaccination in patients with hemophilia. J Med Virol 1993 Oct; 41: 95-8
163. Chalasani N, Smallwood G, Halcomb J, et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998 Mar; 4 (2): 128-32
164. Domínguez M, Bárcena R, García M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000 Jul; 6 (4): 440-2
165. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999 Nov; 318: 304-7
166. Rumi M, Colombo M, Romeo R, et al. Suboptimal response to hepatitis B vaccine in drug users. Arch Intern Med 1991 Mar; 151: 574-8
167. Arslano I, Çetin B. Ìşgüven P, et al. Anti-HBs response to standard hepatitis B vaccination in children and
168. Halota W, Muszyńska M, Pawlowska M. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit 2002; 8 (7): CR516-9
169. Douvin C, Simon D, Charles MA, et al. Hepatitis B vaccination in diabetic patients: randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997 Feb; 20 (2): 148-51
170. Leroy V, Bourliere M, Durand M, et al. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur J Gastroenterol Hepatol 2002 May; 14: 485-9
171. Idilman R, De Maria N, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002 Feb; 97 (2): 435-9
172. Lee SD, Chan CY, Yu MI, et al. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999: 59: 463-8
173. Smart HL, Van Hegan RJ, Triger DR. Impaired response to recombinant DNA hepatitis B vaccine in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 1991; 3 (4): 299-303
174. Rosman AS, Basu P, Galvin K, et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997 Sep; 103: 217-22
175. Bruguera M, Cremades M, Salinas R, et al. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992 Jan; 14 (1): 27-30
176. da Mota Silveira Sasaki MG, Sobroza de Mello R, Focaccia Siciliano R, et al. Response of HIV/AIDS patients to hepatitis B recombinant vaccine. Braz J Infect Dis 1998 Oct; 2 (5): 236-40
177. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals [letter]. AIDS 1994 Apr; 8 (4): 558-9
178. Scolfaro C, Fiammengo P, Balbo L, et al. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 1996 Sep; 10: 1169-70
179. Zuin G, Principi N, Tornaghi R, et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992; 10 (12): 857-60
180. Choudhury SA, Peters VB. Responses to hepatitis B vaccine boosters in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995 Jan; 14 (1): 65-7
181. Clemens R, Sänger R, Kruppenbacher J. et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule: results of a post-marketing surveillance. Vaccine 1997 Mar; 15 (4): 349-52
182. Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20: 3644-9
183. Goldwater PN. Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 1997 Mar; 15 (4): 353-6
184. Leroux-Roels G, Desombere I, Cobbaut L, et al. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 1997 Nov; 15 (16): 1732-6
185. Duval B, Boulianne N, De Serres G, et al. Preadolescent non- and hyporesponders following three doses of heptitis B vaccine need only one more dose. Vaccine 2002; 20: 3632-4
186. Cheng KF, Chang MH, Lee CY, et al. Response to supplementary vaccination with recombinant or plasma hepatitis B vaccine in healthy non-responding children. Vaccine 1994 Aug; 12 (10): 899-902
187. Belloni C, Tinelli C, Orsolini P, et al. Revaccination against hepatitis B virus of non-responding and low-responding infants immunised at birth: a parallel evaluation of rubella and tetanus vaccine. Vaccine 1998 Feb; 16: 399-402
188. Avanzini MA, Belloni C, Soncini R, et al. Increment of recombinant hepatitis B surface antigen-specific T-cell precursors after revaccination of slow responder children. Vaccine 2001 Apr 6; 19 (20-22): 2819-24
189. Wood RC, MacDonald KL, White KE, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993; 270 (24): 2935-9
190. Alimonos K, Nafziger AN, Murray J, et al. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis 1998 Mar; 26: 566-71
191. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002 Dec 1; 35 (11): 1368-75
192. Ingardia CJ, Kelley L, Steinfeld JD, et al. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol 1999 Jun; 93 (6): 983-6
193. Louagie H, Delanghe J, Desombere I, et al. Haptoglobin polymorphism and the immune response after hepatitis-B vaccination. Vaccine 1993 Sep; 11 (12): 1188-90
194. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998 Jun; 51 (6): 593-604
195. Dondi E, Finco O, Mantovani V, et al. Involvement of HLA and C4 in the non responsiveness to hepatitis B vaccine. Fundam Clin Immunol 1996 Jun; 4 (2): 73-8
196. Hohler T, Meyer CU, Notghi A, et al. The influence of major histocompatibility complex class II genes and T-cell Vβ repertoire on response to immunization with HBsAg. Hum Immunol 1998 Apr; 59: 212-8
197. Hsu HY, Chang MH, Ho HN, et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis-B vaccine in Chinese residents in Taiwan. Vaccine 1993 Nov; 11 (14): 1437-40
198. Martinetti M, De Silvestri A, Belloni C, et al. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. Clin Immunol 2000 Dec; 97 (3): 234-40
199. Al-Faleh FZ, Al-Jeffri M, Ramia S, et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect 1999 May; 38: 167-70
200. Antoñanzas F, Garuz R, Rovira J, et al. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. Pharmacoeconomics 1995 May; 7 (5): 428-43
201. Garuz R, Torrea JL, Arnal JM, et al. Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine 1997 Oct; 15 (15): 1652-60
202. Guillen F, Espin MI. Cost-effectiveness analysis of the different alternatives of universal vaccination against hepatitis B in Murcia [in Spanish]. Med Clin 1995; 104: 130-6
203. Da Villa G, Sepe A. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999; 17: 1734-8
204. Hall AJ, Robertson RL, Crivelli PE, et al. Cost-effectiveness of hepatitis B vaccine in the Gambia. Trans R Soc Trop Med Hyg 1993; 87: 333-6
205. Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 1996 May; 32: 197-204
206. Fendrick AM, Lee JH, LaBarge C, et al. Clinical and economic impact of a combination Haemophilus infiuenzae and hepatitis B vaccine. Arch Pediatr Adolesc Med 1999 Feb; 153: 126-36
207. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995 Oct 18; 274 (15): 1201-8
208. Wiebe T, Fergusson P, Horne D, et al. Hepatitis B immunisation in a low-incidence province of Canada: comparing alternative strategies. Med Decis Making 1997; 17 (4): 472-82
209. Krahn M, Guasparini R, Sherman M, et al. Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health 1998 Nov; 88 (11): 1638-44
210. Holliday SM, Faulds D, Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994 Feb; 5 (2): 141-71
211. André FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8 Suppl.: S74-8
212. De Serres G, Duval B, Boulianne N, et al. Importance of attributable risk in monitoring adverse events after immunisation: hepatitis B vaccination in children. Am J Public Health 2001 Feb; 91 (2): 313-5
213. Nadler JP. Multiple sclerosis and hepatitis B vaccination. Clin Infect Dis 1993 Nov; 17: 928-9
214. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991 Nov 9; 338: 1174-5
215. Zipp F, Weil JG, Einhäupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999 Sep; 5 (9): 964-5
216. Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of mulitple sclerosis. N Engl J Med 2001 Feb 1; 344 (5): 327-32
217. Jefferson T, Heijbel H. Demyelinating disease and hepatitis B vaccination: is there a link? Drug Saf 2001; 24 (4): 249-54
218. Sadovnick AD, Scheifele DW. School-based hepatitis B vaccination programme and adolescent multiple sclerosis. Lancet 2000 Feb 12; 355: 549-50
219. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001 Feb 1; 344 (5): 319-26
220. Niu MT, Rhodes P, Salive M, et al. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J Clin Epidemiol 1998 Jun; 51 (6): 503-10
221. Van Damme P. Hepatitis B: vaccination programmes in Europe: an update. Vacccine 2001; 19: 2375-9
222. Poovorawan Y, Theamboonlers A, Hirsch P, et al. Persistence of antibodies to the surface antigen of the hepatitis B virus (Anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol 2000 Sep; 94 (6): 615-21
223. Da Villa G. Rationale for the infant and adolescent vaccination programmes in Italy. Vaccine 2000; 18: S31-4
224. Mele A, Stroffolini T, Zanetti AR, et al. Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination. J Med Virol 2002; 67: 440-3
225. Department of Vaccines and Biologicals of the World Health Organization. State of the World's Vaccines and Immunization [online]. Available from URL: http://www.who.int/vaccines-documents [Accessed 2003 Jan 10]
226. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol 2002; 67: 433-9
227. Yusuf H, Daniels D, Mast EE, et al. Hepatitis B vaccination coverage among United States children. Pediatr Infect Dis J 2001 Nov; 20 (11 Suppl. ): 30-3
228. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996 Sep 18; 276 (11): 906-8
229. Da Villa G, Peluso F, Picciotto L, et al. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996 Nov; 14 (16): 1503-5
230. Da Villa G, Picciottoc L, Elia S, et al. Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups: a comparison in the field. Vaccine 1995; 13 (13): 1240-3
231. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, the Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997 Oct; 15 (15): 1624-30
232. Faustini A, Franco E, Sangalli M, et al. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine 2001 Apr 6; 19: 2812-8
233. Hsu HM, Lu CF, Lee SC, et al. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis 1999 Feb; 179: 367-70
234. Shih HH, Chang MH, Hsu HY, et al. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J 1999 May; 18 (5): 427-32
235. Wainwright RB, Bulkow LR, Parkinson AJ, et al. Protection provided by hepatitis B vaccine in a Yupik eskimo population: results of a 10-year study. J Infect Dis 1997 Mar; 175: 674-7
236. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995 Apr 29; 345: 1089-92
237. Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 2002 Sep 14; 325: 569-72
238. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336 (26): 1855-9
239. Chang MH, Shau WY, Chen CJ, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000 Dec 20; 284 (23): 3040-2
240. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunisation schedules. Health Econ 2000; 9: 19-35
241. Zannolli R, Morgese G. Hepatitis B vaccine: current issues. Ann Pharmacother 1997 Sep; 31: 1059-67
242. Merck & Co. Inc. Recombivax HB®: hepatitis B vaccine (recombinant) prescribing information [online]. Available from URL: http://www.merck.com [Accessed 2003 Feb 14]
243. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001; 19: 877-85
244. Williams IT, Goldstein ST, Tufa J, et al. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatri Infect Dis J 2003 Feb; 22 (2): 157-63
245. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Amercian Academy of Family Physicians (AAFP). MMWR Morb Mortal Wkly Rep 2002 Feb 8; 51: 1-36
246. Resti M, Azzari C, Mannelli F, et al. Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated? Vaccine 1997; 15 (12-13): 1338-40
247. Coursaget P, Leboulleux D, Soumare M. Twelve-year follow up study of hepatitis B immunity of Sengalese infants. J Hepatol 1994; 21: 250-4
248. Fujisawa T, Onoue M, Inui A, et al. Serial changes in titers of antibody to hepatitis B surface antigen after immunization of infants born to mothers with hepatitis B e antigen. J Pediatr Gastroenterol Nutr 1996; 23: 270-4
249. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001 May; 107 (5): 1147-54
250. Lévy-Bruhl D, Desenclos JC, Rebière I, et al. Central demyelinating disorders and hepatitis B vaccination: a risk-benefit approach for pre-adolescent vaccination in France. Vaccine 2002; 20: 2065-71